Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 6 | 2021 | 245 | 0.770 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2010 | 21 | 0.440 |
Why?
|
| Graft vs Host Disease | 8 | 2021 | 163 | 0.350 |
Why?
|
| Transplantation Conditioning | 4 | 2018 | 34 | 0.320 |
Why?
|
| Bone Marrow Transplantation | 2 | 2018 | 149 | 0.280 |
Why?
|
| Graft Survival | 5 | 2018 | 465 | 0.280 |
Why?
|
| Hematologic Neoplasms | 3 | 2021 | 37 | 0.280 |
Why?
|
| Anemia, Sickle Cell | 2 | 2021 | 364 | 0.260 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2018 | 268 | 0.220 |
Why?
|
| Unrelated Donors | 3 | 2018 | 4 | 0.210 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 17 | 0.210 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 15 | 0.210 |
Why?
|
| beta-Globins | 1 | 2021 | 4 | 0.200 |
Why?
|
| Cell Division | 1 | 2003 | 541 | 0.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 70 | 0.200 |
Why?
|
| Alemtuzumab | 2 | 2018 | 10 | 0.190 |
Why?
|
| Ultraviolet Therapy | 1 | 2021 | 9 | 0.190 |
Why?
|
| Phototherapy | 1 | 2021 | 28 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 116 | 0.180 |
Why?
|
| Genetic Therapy | 1 | 2021 | 291 | 0.170 |
Why?
|
| Skin Diseases | 1 | 2021 | 122 | 0.170 |
Why?
|
| Gene Expression | 1 | 2021 | 770 | 0.170 |
Why?
|
| Immune Reconstitution | 1 | 2018 | 4 | 0.160 |
Why?
|
| Child | 9 | 2022 | 6405 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2018 | 168 | 0.150 |
Why?
|
| Transplantation, Homologous | 5 | 2021 | 242 | 0.150 |
Why?
|
| Fetal Blood | 3 | 2007 | 131 | 0.140 |
Why?
|
| Anemia, Aplastic | 1 | 2015 | 10 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2021 | 3187 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 151 | 0.120 |
Why?
|
| HLA Antigens | 3 | 2010 | 82 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 349 | 0.100 |
Why?
|
| Infant | 4 | 2021 | 2891 | 0.100 |
Why?
|
| Blood Donors | 2 | 2009 | 18 | 0.100 |
Why?
|
| Adolescent | 6 | 2021 | 8912 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2010 | 24 | 0.090 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 47 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 79 | 0.090 |
Why?
|
| Lymphocyte Transfusion | 1 | 2009 | 4 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2010 | 215 | 0.080 |
Why?
|
| Acute Disease | 3 | 2021 | 658 | 0.080 |
Why?
|
| Humans | 14 | 2022 | 68618 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1070 | 0.070 |
Why?
|
| Neoplasms | 1 | 2018 | 1667 | 0.070 |
Why?
|
| Survival Rate | 3 | 2016 | 1056 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3259 | 0.070 |
Why?
|
| Adult | 8 | 2021 | 21403 | 0.070 |
Why?
|
| Blood Group Incompatibility | 1 | 2005 | 7 | 0.070 |
Why?
|
| Transplantation Tolerance | 1 | 2005 | 13 | 0.070 |
Why?
|
| Female | 9 | 2021 | 38074 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 506 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 58 | 0.060 |
Why?
|
| Recurrence | 2 | 2007 | 948 | 0.060 |
Why?
|
| Male | 9 | 2021 | 37321 | 0.060 |
Why?
|
| Stem Cell Factor | 1 | 2003 | 39 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 1 | 2003 | 78 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2003 | 108 | 0.050 |
Why?
|
| Culture Media | 1 | 2003 | 155 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2003 | 74 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 18 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 714 | 0.050 |
Why?
|
| Cattle | 1 | 2003 | 475 | 0.050 |
Why?
|
| Lentivirus | 1 | 2021 | 35 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 34 | 0.050 |
Why?
|
| Transgenes | 1 | 2021 | 92 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 145 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 132 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2021 | 312 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2018 | 7029 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2021 | 124 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 271 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2021 | 7277 | 0.040 |
Why?
|
| Time Factors | 2 | 2009 | 4655 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 34 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2018 | 75 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 5717 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 597 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2673 | 0.040 |
Why?
|
| Neutrophils | 1 | 2018 | 204 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2018 | 284 | 0.040 |
Why?
|
| Calcineurin Inhibitors | 1 | 2016 | 24 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 63 | 0.030 |
Why?
|
| Histocompatibility Testing | 2 | 2007 | 38 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 3705 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 1330 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2077 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 951 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 5731 | 0.020 |
Why?
|
| Lymphoma | 1 | 2010 | 116 | 0.020 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2009 | 6 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 174 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2009 | 63 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 69 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 1515 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2005 | 9 | 0.020 |
Why?
|
| Interferons | 1 | 2005 | 36 | 0.020 |
Why?
|
| Animals | 1 | 2003 | 20881 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2005 | 228 | 0.020 |
Why?
|
| Monocytes | 1 | 2005 | 210 | 0.020 |
Why?
|
| Middle Aged | 3 | 2007 | 21147 | 0.010 |
Why?
|
| Myeloablative Agonists | 1 | 2003 | 4 | 0.010 |
Why?
|
| Histocompatibility | 1 | 2003 | 17 | 0.010 |
Why?
|
| Filgrastim | 1 | 2003 | 22 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2003 | 63 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 649 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 742 | 0.010 |
Why?
|